Clinical Trial Update: Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus PEG-Intron for advanced cholangiocarcinoma was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Aiwu Ruth He, MD | Conditions: Advanced Cholangiocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-06-05